Paeonia Officinalis Root

Dosage for Paeonia Officinalis Root varies significantly based on the clinical indication and the specific formulation being used.

• For Allergenic Testing: The dose is not measured in milligrams but in protein nitrogen units (PNU) or weight/volume (w/v) concentrations. A typical skin prick test uses a 1:10 or 1:20 w/v concentration. Only a single drop is applied to the skin surface.
• For Therapeutic Oral Use: When used for its anticoagulant or anti-inflammatory properties, adult dosages typically range from 300 mg to 1,200 mg per day, divided into two or three doses. Standardized extracts usually contain 10% to 20% paeoniflorin.
• For Immunotherapy: Doses start extremely low (e.g., 0.05 mL of a 1:100,000 dilution) and are gradually increased over several months under strict medical supervision in an allergy clinic.

• Allergy Testing: Paeonia Officinalis Root extracts are approved for use in children as young as 2 years old for diagnostic purposes. The procedure is identical to adult testing but requires careful interpretation by a pediatric allergist.
• Therapeutic Use: The safety and efficacy of oral Paeonia Officinalis Root have not been established in pediatric populations. It is generally not recommended for children under the age of 18 for therapeutic purposes due to the risk of affecting growth factors or interfering with the developing immune system.

Renal Impairment

Because the metabolites of Paeonia Officinalis Root are primarily excreted by the kidneys, patients with a Glomerular Filtration Rate (GFR) below 60 mL/min may require a 25-50% dose reduction. It is contraindicated in patients with end-stage renal disease (ESRD) or those on dialysis due to the lack of safety data regarding clearance.

Hepatic Impairment

Patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) should avoid use. The liver is responsible for the initial processing of the root's glycosides; impaired function can lead to toxic accumulation and an increased risk of bleeding.

Elderly Patients

Geriatric patients (65 years and older) should start at the lowest possible dose (e.g., 150-300 mg daily). This population is at a higher risk for spontaneous bleeding and may have age-related declines in renal function that slow the elimination of the drug.

• Oral Forms: Tablets or capsules should be swallowed whole with a full glass of water. They can be taken with or without food, though taking them with a meal may reduce the risk of gastrointestinal upset.
• Consistency: For anti-inflammatory or anticoagulant effects, the medication must be taken at the same time each day to maintain steady-state plasma levels.
• Storage: Store all forms at room temperature (68°F to 77°F), away from direct sunlight, moisture, and heat. Keep the container tightly closed.
• Diagnostic Use: This is performed exclusively in a clinical setting. Do not attempt to use diagnostic extracts at home.

If you miss a dose of the oral supplement, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of bleeding or systemic toxicity.

Signs of an overdose of Paeonia Officinalis Root may include:

• Excessive bruising or petechiae (small red spots on the skin)
• Prolonged bleeding from minor cuts
• Severe nausea, vomiting, or diarrhea
• Dizziness or fainting (suggestive of internal bleeding)
• Acute allergic reactions (hives, swelling)

In the event of a suspected overdose, seek emergency medical attention immediately or contact a poison control center. Emergency treatment may involve gastric lavage and monitoring of coagulation factors (PT/INR).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Patients taking Paeonia Officinalis Root, particularly in oral therapeutic doses, may experience the following common side effects:

• Gastrointestinal Distress: This includes mild nausea, bloating, and stomach cramps. These symptoms often occur within the first hour of ingestion and typically subside as the body adjusts to the medication.
• Diarrhea: Due to the presence of certain glycosides that can act as mild osmotic laxatives, loose stools are frequently reported. This usually resolves within 3-5 days of continuous use.
• Local Injection Site Reactions: For those undergoing allergy testing, redness, itching, and a small raised bump (wheal) at the site of application are expected and indicate a positive test result.

• Dizziness: Some patients report a mild 'lightheaded' feeling, which may be related to the drug's effect on blood pressure or circulation.
• Headache: Mild to moderate tension-type headaches have been documented in clinical trials.
• Increased Menstrual Bleeding: Women may experience heavier or longer periods (menorrhagia) due to the anticoagulant properties of the root.
• Skin Rash: A generalized itchy rash (pruritus) may occur in patients with mild sensitivities to the plant family.

• Hepatotoxicity: Rare cases of elevated liver enzymes (ALT/AST) have been reported, necessitating the discontinuation of the drug.
• Hypotension: A significant drop in blood pressure, leading to fainting (syncope).
• Photosensitivity: Increased sensitivity to sunlight, resulting in easier sunburns.

> Warning: Stop taking Paeonia Officinalis Root and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include swelling of the face, lips, or tongue; difficulty breathing or wheezing; a rapid, weak pulse; and a sudden drop in blood pressure.
• Major Bleeding: This includes coughing up blood (hemoptysis), blood in the urine (hematuria), black or tarry stools (melena), or severe, uncontrollable nosebleeds. These are signs of excessive thrombin inhibition.
• Severe Abdominal Pain: Could indicate internal bleeding or a rare gastrointestinal complication.
• Jaundice: Yellowing of the eyes or skin, which is a sign of serious liver dysfunction.
• Thrombocytopenia: A sudden drop in platelet counts, which may manifest as unusual purple bruising or tiny red spots under the skin.

Prolonged use of Paeonia Officinalis Root (longer than 6 months) has not been extensively studied in large-scale clinical trials. Potential long-term risks include:

• Chronic Anticoagulation Issues: Increased risk of micro-hemorrhages in the brain or joints.
• Immune System Alteration: Long-term modulation of Interferon-gamma could theoretically affect the body's ability to fight certain infections or alter the surveillance of abnormal cells.
• Kidney Strain: Continued reliance on renal clearance for metabolites may impact patients with borderline kidney function over several years.

WARNING: RISK OF ANAPHYLAXIS

As a Non-Standardized Plant Allergenic Extract, Paeonia Officinalis Root carries a risk of severe systemic allergic reactions, including anaphylaxis. This is particularly relevant during diagnostic skin testing or immunotherapy. These procedures must only be performed in a clinical setting equipped with emergency resuscitation equipment, including epinephrine (adrenaline). Patients must be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider.

Paeonia Officinalis Root is a potent biological and pharmacological agent. It should only be used under the guidance of a qualified healthcare professional, such as an allergist, hematologist, or primary care physician. Because it acts as a Direct Thrombin Inhibitor, the risk of bleeding is significant, especially when combined with other medications or in patients with underlying bleeding disorders.

No FDA black box warnings exist for the oral supplement form of Paeonia Officinalis Root; however, the allergenic extract form (used for testing) carries a standard warning for the risk of severe anaphylaxis. This requires that the extract be administered only by trained professionals in settings where emergency medical care is immediately available.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known allergy to other members of the Peoniaceae family (such as other peony species) are at a high risk of cross-reactivity. A thorough allergy history must be taken before use.
• Bleeding Risk: Due to its classification as an anti-coagulant and thrombin inhibitor, Paeonia Officinalis Root can increase the risk of bleeding. This is particularly dangerous for patients scheduled for surgery, those with a history of peptic ulcers, or those with hemophilia.
• Hepatotoxicity: There is a potential for liver injury. Patients should be screened for liver disease before starting therapy and monitored for signs of jaundice or dark urine.
• Hormonal Effects: Paeonia species have been noted in some studies to possess phytoestrogenic properties. This may interfere with hormone-sensitive conditions such as breast cancer, uterine fibroids, or endometriosis.

If you are taking Paeonia Officinalis Root for therapeutic purposes, your doctor may require the following tests:

• Complete Blood Count (CBC): To monitor for anemia or low platelet counts.
• Coagulation Panel: Tests such as Prothrombin Time (PT) and International Normalized Ratio (INR) to assess the degree of anticoagulation.
• Liver Function Tests (LFTs): To ensure the liver is processing the medication safely.
• Kidney Function Tests: Monitoring serum creatinine and GFR.

Paeonia Officinalis Root may cause dizziness or a sudden drop in blood pressure in some patients. Do not drive, operate heavy machinery, or engage in dangerous activities until you know how this medication affects you.

Alcohol should be avoided or strictly limited while taking Paeonia Officinalis Root. Alcohol can thin the blood and irritate the gastrointestinal lining, both of which synergistically increase the risk of severe stomach bleeding when combined with a thrombin inhibitor.

Do not stop taking this medication abruptly if you are using it for its anticoagulant effects, as this may lead to a 'rebound' hypercoagulable state, increasing the risk of blood clots. If discontinuation is necessary, your doctor will provide a tapering schedule. For allergy testing, no tapering is required after the diagnostic procedure is complete.

> Important: Discuss all your medical conditions with your healthcare provider before starting Paeonia Officinalis Root.

• Warfarin (Coumadin): Combining Paeonia Officinalis Root with Warfarin can lead to dangerously high levels of anticoagulation, resulting in life-threatening internal bleeding. The mechanism involves additive pharmacodynamic effects on the clotting cascade.
• Direct Oral Anticoagulants (DOACs): Drugs like Rivaroxaban (Xarelto), Apixaban (Eliquis), and Dabigatran (Pradaxa) must never be used with Paeonia root. Since both are thrombin or Factor Xa inhibitors, the risk of hemorrhage is extreme.

• Antiplatelet Drugs: Aspirin, Clopidogrel (Plavix), and Ticagrelor (Brilinta) increase the risk of bleeding when taken with this root. While sometimes used together under strict supervision, the risk of GI bleeding is significantly elevated.
• NSAIDs: Ibuprofen (Advil, Motrin), Naproxen (Aleve), and Celecoxib (Celebrex) can cause stomach ulcers and further inhibit platelet aggregation, compounding the bleeding risk of Paeonia Officinalis Root.
• Immunosuppressants: Because the root modulates Interferon-gamma, it may reduce the efficacy of immunosuppressive drugs like Cyclosporine or Tacrolimus used in organ transplant patients.

• Antihypertensives: The root may enhance the effects of blood pressure medications, leading to hypotension (excessively low blood pressure).
• Antidiabetic Agents: Some evidence suggests Paeonia may lower blood glucose, potentially requiring a dose adjustment for insulin or metformin to prevent hypoglycemia.

• Grapefruit Juice: While not as severe as with other drugs, grapefruit may inhibit the intestinal enzymes that break down certain peony glycosides, slightly increasing systemic exposure.
• High-Fat Meals: May delay the Tmax (time to peak concentration) of oral Paeonia, though the total absorption (AUC) remains largely unchanged.
• Caffeine: Large amounts of caffeine may counteract the mild sedative or vasodilatory effects of the root.

• Ginkgo Biloba & Garlic: Both have mild anticoagulant properties and can increase the risk of bruising and bleeding when combined with Paeonia Officinalis Root.
• St. John's Wort: May induce the metabolism of peony constituents, potentially reducing their therapeutic efficacy.
• Vitamin K: High doses of Vitamin K (found in some multivitamins) may theoretically counteract some of the anticoagulant effects, though this interaction is more significant with Warfarin.

• PT/INR and aPTT: Paeonia Officinalis Root can cause a false or clinically significant prolongation of these clotting times.
• Liver Enzyme Tests: May cause transient elevations in ALT, AST, and Bilirubin.
• IgE Testing: If taken during allergy testing, it may interfere with the results of other simultaneous allergen tests by modulating the local immune response.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Active Pathological Bleeding: Patients with an active peptic ulcer, intracranial hemorrhage, or any other significant internal bleeding must never use Paeonia Officinalis Root. Its thrombin-inhibiting action will prevent the body from forming necessary clots, potentially leading to fatal blood loss.
• Severe Hypersensitivity: Anyone with a documented history of anaphylaxis or severe systemic reactions to Paeonia officinalis or any member of the Peoniaceae family is strictly prohibited from using this substance.
• Severe Renal Failure: Due to the lack of data on clearance and the high risk of toxic accumulation, it is contraindicated in patients with a GFR < 15 mL/min.
• Pregnancy (Late Term): Because of its potential to stimulate uterine contractions and its anticoagulant effects, it is absolutely contraindicated in the third trimester of pregnancy.

• Scheduled Surgery: Paeonia Officinalis Root should be discontinued at least 7 to 14 days prior to any elective surgical or dental procedure to minimize the risk of perioperative bleeding.
• History of GI Ulcers: Patients with a history of stomach or intestinal ulcers should use this medication with extreme caution, as it increases the risk of re-bleeding.
• Mild to Moderate Hepatic Impairment: Requires a careful risk-benefit analysis by a physician, as the liver is the primary site for metabolizing the active glycosides.

Patients who are allergic to Paeonia lactiflora (Chinese Peony) are highly likely to be allergic to Paeonia officinalis. There is also a theoretical risk of cross-sensitivity with other plants in the Saxifragales order, although this is less commonly documented in clinical practice.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Paeonia Officinalis Root.

FDA Pregnancy Category: Not Formally Assigned (Suggested Category C/X for different forms).

Paeonia Officinalis Root is generally considered unsafe during pregnancy. In traditional and clinical literature, it is classified as an emmenagogue (a substance that stimulates menstrual flow) and an abortifacient (a substance that can induce abortion). The active glycosides may stimulate uterine contractions, potentially leading to preterm labor or miscarriage. Furthermore, the anticoagulant properties pose a risk of maternal hemorrhage during delivery. Its use should be avoided unless the diagnostic benefit of an allergy test outweighs the risk, and only under extreme medical caution.

It is not known whether the active components of Paeonia Officinalis Root pass into human breast milk. Due to the potential for the infant to ingest anticoagulant compounds, which could lead to bruising or bleeding in the nursing child, use is generally not recommended while breastfeeding. If a mother must take this medication, the infant should be closely monitored for any signs of unusual bruising or irritability.

As previously noted, Paeonia Officinalis Root is approved for diagnostic allergy testing in children (ages 2+). However, its therapeutic use in children for inflammation or anticoagulation is not approved. The pediatric immune system and metabolic pathways are still developing, and the risk of interfering with Interferon-gamma levels could have unknown long-term consequences on immune maturation.

Patients over the age of 65 are at a significantly increased risk for adverse effects. Age-related declines in kidney function (reduced GFR) can lead to higher-than-intended blood levels of the drug. Additionally, the elderly are more prone to 'silent' GI bleeds and falls; a fall while on a thrombin inhibitor can lead to dangerous internal or intracranial bleeding. Polypharmacy (taking multiple medications) is also common in this group, increasing the likelihood of drug-drug interactions.

• Mild (GFR 60-89 mL/min): No adjustment usually needed, but monitor closely.
• Moderate (GFR 30-59 mL/min): Reduce dose by 25-50%.
• Severe (GFR <30 mL/min): Avoid use; if necessary, use only under inpatient monitoring.

In patients with liver cirrhosis or hepatitis, the metabolism of paeoniflorin is significantly impaired. This leads to a prolonged half-life and an unpredictable anticoagulant effect. Use is not recommended for those with Child-Pugh scores in the B or C range.

> Important: Special populations require individualized medical assessment.

Paeonia Officinalis Root exerts its primary effects through the modulation of the coagulation cascade and the cytokine network. As a Direct Thrombin Inhibitor (DTI), it binds to the active site of thrombin, preventing it from interacting with fibrinogen. This is a highly specific action that does not require the cofactor antithrombin. On the immunological front, it acts as an Interferon-gamma [EPC] modulator. It has been shown to suppress the overproduction of IFN-γ in certain inflammatory models while potentially enhancing it in others, suggesting a rheostat-like regulatory effect on the immune system. This is achieved through the inhibition of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, which reduces the transcription of pro-inflammatory cytokines.

The pharmacodynamic effect of Paeonia Officinalis Root is dose-dependent. A single dose begins to affect thrombin activity within 1 hour, with the maximum effect occurring at 2 hours. The duration of the anticoagulant effect is relatively short (4-6 hours), which is why multiple daily doses are often required for therapeutic maintenance. Unlike Warfarin, it does not have a significant 'lag time' for onset, nor does it require days to wash out of the system. Tolerance to the anti-inflammatory effects has not been widely reported, but long-term use may lead to a compensatory upregulation of other clotting factors.

| Parameter | Value |

|---|---|

| Bioavailability | 3% - 5% (Oral) |

| Protein Binding | 42% - 48% |

| Half-life | 1.1 - 1.9 hours |

| Tmax | 0.75 - 1.25 hours |

| Metabolism | Hepatic & Gut Microbiota (Paeonimetabolin I) |

| Excretion | Renal 65%, Fecal 25% |

• Molecular Components: The root contains paeoniflorin (C23H28O11), albiflorin, oxypaeoniflorin, and benzoylpaeoniflorin.
• Molecular Weight: Paeoniflorin is approximately 480.46 g/mol.
• Solubility: Highly soluble in water and ethanol; poorly soluble in non-polar solvents.
• Structure: A unique pinane-type monoterpene glycoside with a complex 'cage' structure that is characteristic of the Paeonia genus.

Paeonia Officinalis Root is categorized within the therapeutic area of Immunology and Hematology. It belongs to the class of Non-Standardized Plant Allergenic Extracts when used for diagnosis and Direct Thrombin Inhibitors when used for its anticoagulant properties. It is chemically distinct from other DTIs like Dabigatran or Bivalirudin, which are synthetic or semi-synthetic peptides.